ARTICLE | Distillery Therapeutics


November 9, 2016 9:05 PM UTC

Mouse studies suggest an ENPP2 inhibitor could help treat liver fibrosis in NASH. In an in vitro assay, a previously identified fluoroindoylthiofluorobenzoic acid analog (PAT-505) inhibited ENPP2 activity with an IC50 of 2.0 nM. In a mouse model of NASH-associated liver fibrosis, the compound decreased numbers of inflammatory cells in the liver compared with vehicle. In another mouse model of NASH-associated fibrosis, the compound decreased liver fibrosis and hepatic levels of three markers of liver fibrosis. Next steps by PharmAkea Therapeutics Inc. and Celgene Corp. include planning a clinical trial of the lead ENPP2 inhibitor for 2017.

Galapagos N.V. has GLPG1690, a selective ENPP2 inhibitor, in Phase II testing to treat pulmonary fibrosis and Phase I testing to treat pulmonary disease and chronic obstructive pulmonary disease (COPD)...

BCIQ Company Profiles

PharmAkea Therapeutics Inc.

BCIQ Target Profiles

Autotaxin (ENPP2) (ATX)